Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cerecor Inc.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Ichorion Therapeutics, Inc.
- Trx Pharmaceuticals, LLC
- Zylera Phamaceuticals, LLC
- Aevi Genomic Medicine, Inc.